A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma

Abstract Background Combination checkpoint inhibition therapy with yttrium-90 (Y90) radioembolization represents an emerging area of interest in the treatment of advanced hepatocellular carcinoma (HCC). HCRN GI15-225 is an open-label, single-arm multicenter, pilot study (NCT03099564). Methods Eligib...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The oncologist (Dayton, Ohio) Jg. 29; H. 3; S. 270 - e413
Hauptverfasser:	Yu, Shawn, Yu, Menggang, Keane, Barry, Mauro, David M, Helft, Paul R, Harris, William P, Sanoff, Hanna K, Johnson, Matthew S, O’Neil, Bert, McRee, Autumn Jackson, Somasundaram, Ashwin
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	US Oxford University Press 01.03.2024
Schlagworte:	Care and treatment Clinical Trial Results Combined modality therapy Hepatoma Liver cancer Medical prognosis Methods Pilot projects Radiotherapy United States pembrolizumab glass Y90 radioembolization hepatocellular carcinoma immunotherapy TARE
ISSN:	1083-7159, 1549-490X, 1549-490X
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!